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BEYOND PROSTATE-SPECIFIC ANTIGEN 
ALTERNATIVES FOR PROSTATIC NEOPLASM SCREENING 
KEVIN K. YU 
ABSTRACT 
 Prostate adenocarcinoma (PCa) is one of the most prevalent cancers in the world. 
Second only to lung cancer, the key to its successful treatment is in its early detection. 
With the introduction of prostate-specific antigen in the early 1990s, a screening test 
involving measuring levels of this protein was developed to detect PCa in asymptomatic 
individuals. This test is also known as the PSA test. PCa-specific mortalities have been in 
decline since the test’s introduction. 
 Despite this decline, recent studies have called the efficacy of the PSA test into 
question. Two large randomized controlled trials conducted in the US and Europe reveal 
contradicting results as to PSA’s accuracy and usefulness. Concerns of overdiagnosis and 
overtreatment as the result of using PSA screening has led to many national organizations 
recommending caution or even recommending against its use. Through a thorough review 
of a large collection of current PCa literature, this study reviews the flaws of using PSA 
to screen for PCa and investigates alternative approaches currently being pursued through 
active research to make PCa early detection more accurate. These approaches include 
improving the accuracy of the PSA screen using PSA-derived testing methods, using 
PCa-induced epigenetic modifications as a new target for PCa screening, and using urine 
biomarkers. All of these methods were compared using area under the curve (AUC) 
values obtained via receiver operating characteristic analysis. 
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 Each method has its own flaws but by comparing each of the different 
approaches, I was able to conclude that out of the currently available screening methods, 
screening for Engrailed-2 protein in urine is the most promising screening method with 
the highest AUC values compared to the other methods. Although this method has been 
introduced in the UK, it has not been introduced in the US yet. Epigenetic screening 
methods hold the most promise for accurate PCa screening in the future as it confers the 
highest accuracy in detecting PCa. However, as it hasn’t been shown that epigenetic 
modifications can be easily obtained in the urine or blood serum for easy and accurate 
screening, I believe more work has to be done in order for it to be successful in being 
applied as a screening test. By determining the most promising screening type, we can 
focus resources and efforts towards finding a way to detect PCa early, allowing for 
successful treatment.  
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INTRODUCTION 
Prostate cancer is one of the most prevalent cancers worldwide. It has been 
estimated in various developed countries that the number of new prostate cancer cases 
eclipsed that of lung and bronchus cancer in 2011 and is one of the leading cancer-related 
causes of mortality and morbidity in the United States. According to the American 
Cancer Society (ACS), 217,730 cases are diagnosed each year with 63% of prostate 
cancer cases occurring in men over age 65 (“What is prostate cancer?,” 2014). One in 
seven men will be diagnosed with prostate cancer during his lifetime (“What is prostate 
cancer?,” 2014). It is predicted by the ACS that in 2014, 233,000 new cases of prostate 
cancer will be diagnosed and about 29,480 men will die of prostate cancer (“What is 
prostate cancer?,” 2014). With the aging population of the US, the number of elderly men 
who are affected by prostate cancer will likely increase (Wiener & Tilly, 2002). Like in 
most other neoplasms, the key to the successful treatment of prostatic neoplasms is in 
their early detection and treatment. As such, there has been a push to develop screening 
methods in an effort to detect prostate cancer early.  
I. The Anatomy of the Prostate: 
 
The prostate gland is a dense organ that surrounds the urethra distal to the urinary 
bladder and ventral to the rectum. Slightly larger than a walnut at around 2 cm x 3 cm x 4 
cm and weighing around 20 grams, it is part of the accessory sex gland system in human 
males that synthesizes and secretes both organic and inorganic components of the seminal 
fluid believed to be important for sperm survival in the female reproductive tract 
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(Mescher, 2010). The anatomy of the prostate is divided into 4 distinct zones that were 
first described by Dr. John E. McNeal in 1968 (Costello & Corcoran, 2013). The four 
zones that comprise the prostate are the peripheral zone, the central zone, the transitional 
zone, and the periurethral glands. The main glands of the prostate are found within the 
peripheral zone whereas the submucosal and mucosal glands are within the central and 
transitional zones respectively. Each of the zones occupy 75%, 25%, 5-10%, and <1% of 
the prostate respectively (Costello & Corcoran, 2013). 
 
The majority of the diagnosed cases (95%) of prostate cancer are 
adenocarcinomas resulting from the glands from the peripheral zone (Shevchuk & 
Robinson, 2013). Although there are other types of prostate cancers that originate from 
other cell types, they are a minority of prostate cancer cases and are out of the scope of 
this particular study. 
Figure 1 - Prostate Anatomy: 
This figure illustrates the anatomy of the prostate. The majority of all PCa cases occur in the peripheral 
zone which is the largest of the four zones described by Dr. McNeal. Although not shown in this particular 
illustration, the periurethral glands are at the border of the prostatic urethra and the transitional zone. 
Figure taken from: Anthony Mescher. (2010). Junqueira’s Basic Histology Text & Atlas (12th Edition.). 
United States of America: The McGraw-Hill Companies, Inc. 
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II. Prostate Adenocarcinoma: 
Prostate Adenocarcinoma (PCa) is a cancer originating from the glands of the 
prostate that predominantly affects men older than 50 years of age. Histologically, it is 
characterized by changes in the nucleus of glandular cells with increases in cell density 
and nuclear heterochromativity (Shevchuk & Robinson, 2013). Physically, it is 
characterized by changes in size, shape, or texture of the prostate. Symptoms of PCa 
include urinary urgency, hematuria, impotence, frequent need to urinate at night 
(nocturia), and loss of bladder or bowel control due to advance stages of the cancer 
applying pressure on the spinal cord (Mayo Clinic Staff, 2013). More advanced stages of 
PCa are often characterized by pain in the hips, spine, and ribs due to metastasis and 
possible weakness or numbness in the legs or feet (“What is prostate cancer?,” 2014). 
 
 
 
 
Figure 2 – Prostate Adenocarcinoma Adjacent to Normal Prostate Tissue 
This figure depicts the histological differences between PCa and normal prostate tissue. The left side of the 
figure is abnormal prostate tissue typical of PCa while the right side of the figure shows normal prostate 
tissue. Note the increased cell density in the PCa tissue where glandular spaces are small compared to 
normal tissue. 
Figure taken from: Sean Linford. (2001, February). Prostate Cancer. Medical Genetics University of Utah. 
Retrieved May 13, 2014, from http://medgen.genetics.utah.edu/ 
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A. Gleason Scoring System for Prostate Cancer: 
In order to assess the prognosis of PCa, the cancers are graded based on a scoring 
system called the Gleason scale. It utilizes a 2 to 10 scale system where lower grade 
cancers are less dangerous to patients while higher grade cancers are more deadly. The 
score is determined based on the appearance of the cells in histological sections obtained 
during prostate biopsies. These patterns are graded on a 1 to 5 system where a well-
differentiated pattern is given the score of 1 and the most poorly-differentiated pattern is 
given the score of 5 (Figure 3). Pathologists first assign a primary grade that reflects the 
dominant pattern observed (>50% of the tissue) then add a secondary grade that reflects 
the pattern observed in the remainder of the tissue (<50%) (Humphrey, 2004). This 
number is the final Gleason score (GS) that physicians use to determine treatment 
modalities. GS and their respective risks to the patient can be found in the table below 
(“What is prostate cancer?,” 2014). 
Gleason Score Description of PCa Risk  
<6 - Low-grade, well differentiated, and slow 
growing 
Low risk 
7 - Intermediate grade and moderately 
differentiated. 
- Need to be assessed with PSA level with 
tumor volume. 
Moderate risk 
>7 - High grade and poorly differentiated. 
- Aggressive cancers that are hard to treat 
and have a higher chance of recurrence. 
High risk 
*This table displays the risk stratification of PCa using Gleason scores important in aiding physicians in 
deciding whether or not treatment is warranted. A Gleason score of 7 can fall in either moderate or high 
risk depending on the primary pattern. 
Table 1 – Gleason Scores and 
Corresponding Risks to Patients*: 
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B. Prostate Cancer Risk Factors: 
There are a multitude of risk factors associated with PCa. The most significant of 
these is age with an increased incidence of PCa in men older than 50. According to the 
Center for Disease Control (CDC), the percentage of 40-year old men who develop PCa 
within 10 years is around 0.34%. On the other hand, the percentage of men at an age of 
50 who develop PCa within the next 10 years increases 6.8 fold to 2.31%. It has been 
Figure 3 – Gleason’s Pattern: 
This figure depicts the histological pattern by which pathologist use to grade PCa tissue samples. A grade of 
1 to 5 is assigned based on tissue patterns. The total Gleason score is the combination of the primary score 
which is representative of >50% of the tissue and the secondary score which represents the remaining tissue. 
Figure taken from: U.S. National Institutes of Health, National Cancer Institute. (n.d.). SEER Training: 
Morphology & Grade. National Cancer Institute SEER Training Modules. Retrieved May 5, 2014, from 
http://training.seer.cancer.gov/prostate/abstract-code-stage/morphology.html 
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shown that 50% of men in the 70-80 age group show histological signs of PCa (“CDC - 
Prostate Cancer Risk by Age,” 2013).  
PCa has also been characterized to run in families with a more than doubled 
increased risk if another male in the immediate family have or have had prostate cancer. 
This finding hints at possible genetic factors that lead to the development of PCa that are 
passed down through generations. It is suggested that changes in the BRCA1 or BRCA2 
gene can increase risk of PCa but they only account for a small subset of cases overall 
(“What is prostate cancer?,” 2014). 
Ethnicity and race are also significant risk factors (Figures 4 and 5). It has been 
suggested in 2011 through the combined data published by the CDC and the National 
Cancer Institute (NCI) in 2009, the incidence rate was highest in African American 
followed by Caucasian and Hispanic men with similar trends for mortality rates (“CDC - 
Prostate Cancer Rates by Race and Ethnicity,” 2013). The reason for the ethnic and racial 
discrepancies in the likelihood of having PCa is currently unknown.  
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Figure 4 – Prostate Cancer Incidence Rates by Race and Ethnicity in the US from 1999 to 2010: 
The incidence rate of prostate cancer in the U.S. formulated from the combined data of the CDC and NCI. 
The incidence of prostate cancer is highest among Black Americans followed by Caucasians, Hispanics, 
Asian and Asian Pacific Islanders, and American Indian/Alaskan Natives. Note the higher prostate cancer 
incidence rates in the Black population and the lower prostate cancer incidence rates in Asians and Pacific 
Islanders compared to the other races and ethnicities. 
Figure taken from: CDC - Prostate Cancer Rates by Race and Ethnicity. (2013, August 12). Retrieved April 
25, 2014, from http://www.cdc.gov/cancer/prostate/statistics/race.htm 
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Figure 5 – Prostate Cancer Death Rates by Race and Ethnicity in the US from 1999 to 2010: 
The death rates of prostate cancer are highest among Black Americans followed by Caucasians, Hispanics, 
American Indian/Alaskan Natives, and Asian and Asian Pacific Islanders. 
Figure taken from: CDC - Prostate Cancer Rates by Race and Ethnicity. (2013, August 12). Retrieved April 
25, 2014, from http://www.cdc.gov/cancer/prostate/statistics/race.htm 
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III. Prostate-Specific Antigen: 
 
Prostate-Specific Antigen (PSA) was first discovered in 1979. A member of the 
tissue kallikrein family, PSA is a serine protease that is secreted into the lumen of 
prostate glands by the ductal and acinar epithelium. Its function is to cleave semenoglin I 
and II in the seminal coagulum to liquefy semen for greater sperm movement (Balk et al., 
2003). PSA is a histiotypic product of the human prostate and, as implied by its function, 
is primarily found in semen. Small quantities of PSA is also found in the serum of 
healthy men. 
The fundamental concept underlying screening tests for diseases differs from that 
of diagnostic tests. While diagnostic tests seek to identify a specific disease based on the 
symptoms that a patient is already presenting, a screen seeks to identify diseases in 
symptom-free individuals (Ilic et al.,  1996). Prior to the discovery of PSA, PCa was 
primarily screened for via digital rectal examination (DRE), first proposed by Dr. Hugh 
Hampton Young in 1905 (Hilton,  & Parekh, 2013). In a DRE a physician inserts a 
gloved finger into the rectum of the patient and physically feels for changes to the 
prostate anatomy (“What is prostate cancer?,” 2014). If a palpable change is discovered, 
the patient would then undergo a needle biopsy that obtains 4 or fewer tissue samples of 
his prostate to definitively diagnose PCa. This was associated with significant procedure-
related morbidity. In addition to the morbidity associated with biopsies, due to the nature 
of the DRE, not all PCa can be felt and discovered as the DRE was limited to the surface 
of the dorsal side of the prostate (Ilic et al., 2011). As a result, significant numbers of PCa 
cases were left undetected and untreated until the diseased progressed to a more advanced 
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stage. At this point, patient prognoses were grim. There was a need for a more definitive 
way to screen for PCa. 
In 1981, increased circulating levels of PSA were found in patients with PCa as 
the result of prostate neoplasm development (Kuriyama et al., 1981). This discovery and 
the tissue specific nature of PSA led to the Food and Drug Administration (FDA) 
approval of its use in 1986 to evaluate response to treatment of PCa that was screened via 
DRE and diagnosed via biopsies (“Prostate-Specific Antigen (PSA) Test - National 
Cancer Institute,” 2010). Ultimately, due to the relative simplicity of the test and its 
deemed usefulness at the time, the PSA blood test was approved by the FDA for use in 
PCa screening in conjunction with DRE in 1994 for asymptomatic men (“Prostate-
Specific Antigen (PSA) Test - National Cancer Institute,” 2010).  
As PSA screening helped physicians with the early diagnosis of PCa where active 
treatment may reduce PCa specific mortality, PCa specific mortality declined steadily 
since PSA’s introduction in the early 1990s. Two independent models from the Fred 
Hutchinson Cancer Research Center (FHCRC) and the University of Michigan (UMICH) 
have shown a decrease in PCa mortality that coincide with the introduction of PSA 
screening in the early 1990s (Etzioni et al., 2008). According to the FHCRC and UMICH 
models, PSA screening contributed 45% to 70% respectively of the decrease in PCa-
specific mortalities up to the year 2000 since the start of its widespread use as a screening 
test (Etzioni et al., 2008). To this day, the PSA blood test measuring circulating PSA 
levels in a patient’s serum used in conjunction with the DRE remain the predominant 
screening method for PCa. Currently, PSA tests use a classical 4.0 ng/ml cutoff for 
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normal PSA levels and it is suggested men who have PSA levels above 4.0 ng/ml 
undergo biopsy to definitively determine PCa presence. The test is done every few years 
for normal-risk men above the age of 40 if requested by patients. 
IV. Concerns of PSA Screen Efficacy in Screening for PCa: 
The majority of the recent literature seems to be in agreement that while PSA 
testing is a good first step in the detection of the early signs of PCa, the test is limited in 
its specificity and sensitivity for the diagnosis of PCa and there is currently a lack of 
consensus about using the PSA test to screen for PCa in asymptomatic men (Thompson et 
al., 2004). A multitude of efficacy concerns and limitations has led many major 
urological and cancer organizations in the United States to advise caution when testing 
for PCa through PSA screening. 
A. Unknown benefit in reducing PCa-specific mortalities:  
In an effort to examine the usefulness of PSA testing in reducing PCa-specific 
mortalities for patients, various national organizations performed long-term randomized 
control trials (RCT) to determine whether PSA tests are truly able to decrease the chances 
of a man dying from PCa. According to the Prostate, Lung, Colorectal, and Ovarian 
(PLCO) Cancer screening trial done in the United States by NCI, while the PSA test 
increased the incidence of PCa in a group of men randomly selected to undergo the PSA 
test versus the control group in the RTC, the rates of death from PCa between the two 
groups were the same (Andriole et al., 2012). Specifically, Andriole et al. (2012) found a 
statistically significant relative increase of 12% in the incidence of PCa detected while 
there was a statistically insignificant decrease in PCa-specific mortalities. The authors 
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attribute this slight decrease in PCa-specific mortalities to improvements of treatment 
modalities rather than directly arising from PSA screening. 
On the other hand, the European Randomized Study of Screening for Prostate 
Cancer (ERSPC), a similar large scale RCT, showed a decreased rate of death from PCa 
in the group that was screened versus the control group with its 11-year follow up results 
(Schröder et al., 2012). Schröder et al. (2012) showed a 20% reduction in the risk of 
patients dying from PCa following PSA testing in the 55-69 age group who are most at 
risk for developing PCa. Although the finding seems positive, it comes with an important 
caveat: the same RCT in 2009 estimated 75.9% of men who underwent biopsy as a result 
of an elevated PSA value had a false positive PCa result due to the PSA test (Schröder et 
al., 2009). The contradicting evidence regarding the true effect of PSA testing on 
reducing PCa-specific mortalities and the high probability of false positive readings has 
called the efficacy of the PSA screen into question.  
B. Other Prostate Abnormalities leading to Increases in PSA levels 
Despite its primary use of detecting PCa, it is also important to note that PSA is 
prostate-specific but not PCa-specific. Levels of PSA are also found to rise as the result 
of various other prostate diseases (Van Neste et al., 2012). One of such diseases is Benign 
Prostatic Hyperplasia (BPH). This is an extremely common condition in older men with 1 
in 4 men experiencing signs by the age of 55. By the age of 75, this increases to 1 in 2 
men experiencing symptoms and signs (Mayo Clinic Staff, 2011). Like PCa, men with 
BPH exhibit an enlarged prostate. Patients suffering from BPH also experience urinary 
urgency and nocturia (Mayo Clinic Staff, 2011). Notwithstanding certain similarities 
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between the two conditions, it is important to differentiate between the two conditions as 
PCa can be aggressive and life-threatening whereas BPH is not. Because BPH is also 
characterized with an increase in PSA levels, it can be sometimes difficult to differentiate 
between PCa and BPH simply through a PSA blood test and a DRE without the aid of 
biopsies. 
Prostatitis is another prostate condition that can cause a rise in levels of 
circulating PSA in a patient’s serum (Van Neste et al., 2012). Prostatitis covers a series of 
disorders that include bacterial infections to chronic conditions that are characterized by 
inflammation of the prostate. Prostatitis is a common condition that occurs in as much as 
9% of men in their lifetimes and its symptoms vary and are hard to pinpoint (Roberts & 
Jacobsen, 2000). Patients suffering prostatitis often have enlarge prostates and can have 
elevated PSA levels that can confound PSA tests for PCa (Mayo Clinic Staff, 2014). 
C. Possibility of overdiagnosis and overtreatment: 
Since the introduction of PSA in the monitoring of patients treated for PCa in 
1986, there has been a dramatic increase in the incidence of PCa. From 1986 to 2005, the 
incidence of PCa has increased by 26% relative to the incidence rates prior to 1986 
(Welch & Albertsen, 2009). Of different age groups, the highest increases in incidence 
rates relative to 1986 occurred in the 20-49, 50-59, and 60-69 age groups with the 20-49 
age group increasing more than 7-fold relative to incidence rates prior to 1986 with 
50500 more men diagnosed with PCa (Figure 6). One might question why the authors 
chose to use 1986 as the base year when FDA approved of PSA screening in 1994. The 
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authors justify this choice through the argument that investigations into PSA screening 
begun in 1987 thus increasing the amount of PCa detected (Welch & Albertsen, 2009). 
 
This increase in PCa detection through the implementation of PSA can be a 
double-edged sword. While the increased PCa detection can lead to a decrease in PCa-
specific mortality, one must also recognize the possibility of increased overdiagnosis 
along with the increase in incidence. In fact, the ERSPC study estimate that the rate of 
overdiagnosis can be as high as 50% that may lead to overtreatment of indolent cancers 
that are found through the PSA screen (Schröder et al., 2009). These indolent cancers are 
currently difficult to differentiate from aggressive and malignant cancers. It was noted by 
Schröder et al. (2012) in the 11-year follow-up that in order to save one patient from a 
Figure 6 – Age-specific PCa Incidence Rates Relative to 1986: 
With the introduction of PSA as a possible screening method for PCa, the incidence rates increased 
dramatically for the 20-49, 50-59, and 60-69 age groups. Although this may seem beneficial in the treatment 
of PCa, the increase in PCa diagnosis due to PSA screening may actually be due to an increase in 
overdiagnosis that can lead to overtreatment. 
Figure taken from: Welch, H. G., & Albertsen, P. C. (2009). Prostate Cancer Diagnosis and Treatment 
After the Introduction of Prostate-Specific Antigen Screening: 1986–2005. Journal of the National Cancer 
Institute, 101(19), 1325–1329. doi:10.1093/jnci/djp278 
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clinically significant case of PCa, 1055 men would have to be screened and 37 cases of 
PCa would need to be detected. This leads to a potentially staggering amount of 
overtreatment for indolent cancers that are otherwise clinically insignificant and will not 
adversely affect the patient at which point the treatment will cause more harm than good. 
As a result, it is a concern that the widespread use of PSA testing will lead to increased 
amount of false-positives and cause unnecessary treatment-associated morbidities such as 
sepsis, bleeding, hospitalization, and anxiety in patients who are otherwise healthy 
(Truong et al., 2013). 
D. Concerns about accuracy of PSA tests: 
Even though PSA blood tests are the predominant way to screen for PCa, the 
exact ranges for normal and abnormal PSA levels that are indicative of PCa are still 
debated. Currently, the most commonly accepted upper bound normal PSA circulation 
levels is 4.0 ng/ml (Hayes & Barry , 2014). PSA circulation levels above 4.0 ng/ml is 
considered abnormal and a biopsy may be considered to definitively determine the 
presence of PCa.  
Recently there have been a number of studies in the literature calling this upper 
bound into question. It has been found in the Prostate Cancer Prevention Trial (PCPT) 
that biopsies conducted on men who never had PSA levels above 4.0 ng/ml, some had 
malignant PCa when their PSA levels measured as low as 0.5 ng/ml (Thompson et al., 
2004). This presents a particularly challenging hurdle for PSA screening as the currently 
accepted 4.0 ng/ml upper boundary level causes many locally contained but moderately 
differentiated cancers to be missed. According to the PCPT, 15% of men with PSA of 0 
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ng/ml to 4.0 ng/ml have PCa and of those, 15% have high Gleason grade disease 
(Thompson et al., 2004). 
However, one cannot just arbitrarily lower the accepted 4.0 ng/ml boundary to 
simply increase the sensitivity of the screen as this will increase the number of people 
who are overdiagnosed with the disease. Because many other noncancerous prostate 
conditions like BPH and prostatitis as well as benign tumors can cause an increase in 
PSA levels, lowering the upper limit of normal PSA levels from 4.0 ng/ml may result in 
increasing number of false-positives as well as possible overdiagnosis and overtreatment. 
The United States Preventive Services Task Force (USPSTF) has estimated that if the 
lower bound was decreased to 2.5 ng/ml in an attempt to increase the sensitivity of the 
PSA screening test, it would result in a doubling of men in the 40-69 age group with 
abnormal PSA levels with the majority being false-positives (Moyer, 2012). This increase 
is undesirable as too many indolent cancers and noncancerous conditions will be falsely 
categorized as PCa and the resultant procedures to definitively diagnosis PCa will 
increase healthcare costs in addition to causing unnecessary harm to the patients. To this 
date, there is no PSA level cutoff that can guarantee any patient that they are free of PCa.  
Additionally, if the PSA cutoff was lowered, one cannot reliably use biopsies to 
make up for the decrease in specificity of the PSA screening test. Because biopsy 
detection rates vary with the amount of samples taken per biopsy, there is a possibility 
that if too few tissue samples were taken that critical cancers can be missed. On the other 
hand, if a saturation biopsy procedure was employed, the problem with an increase in the 
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detection of indolent cancers would once again occur. As a result, the accuracy of PSA 
tests cannot be precisely determined (Moyer, 2012). 
E. Costs associated with overdiagnosis and overtreatment: 
The costs associated with overdiagnosis and overtreatment that result from the 
PSA blood test are not trivial. As positive PSA screen results are usually followed by a 
biopsy to definitively determine the presence of PCa, there are associated side effects that 
can negatively affect a patient. Side effects of needle biopsy following a positive PSA 
screen include hematospermia, hematuria, pain, fever, urinary retention, and prostatitis or 
urosepsis (Ilic et al., 2011). The percentage of men affected by these side effects are 
50.4%, 22.6%, 7.5%, 3.5%, 0.4%, and 0.5% respectively (Ilic et al., 2011). About 20% of 
the men who have had needle biopsies view future biopsies negatively and 1.4% were 
hospitalized for complications that have resulted from needle biopsies (Moyer, 2012). 
Beyond these immediate side effects, it has been shown that as many as 90% of 
the patients who tested positive in the PSA test have early treatment that includes 
radiation therapy and/or surgery despite the fact that the tumor may be indolent and not 
cause them any harm (Moyer, 2012). These patients are then subject to the side effects of 
these treatments including erectile dysfunction, urinary incontinence, and bowel 
dysfunction (“Prostate-Specific Antigen (PSA) Test - National Cancer Institute,” 2010). 
Since PSA screening has the high potential to overdiagnose (as much as 50%), it is 
reasonable to infer that many of the patients unnecessarily suffer these side effects as a 
result of interventions targeting PCa.  
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Other than physical costs associated with overdiagnosis and overtreatment, 
monetary costs incurred after a positive PSA screening test are also major factors that 
need to be considered in regards to using PSA to screen for PCa. In the year 2000, the 
cost associated with PCa diagnosis and treatment accounted for $1.3 billion in American 
health expenditure (Shteynshlyuger & Andriole, 2011). Treatment costs range from 
$20,000 to $50,000 depending on the procedure and the patient’s risk level and include 
radiation treatments and surgeries (Table 2) (Cooperberg et al., 2013). Since the inception 
of PSA screening tests, it has been estimated that the number of men diagnosed with PCa 
has increased by 1.3 million. Of these 1.3 million, 56500 deaths had been averted due to 
PCa screening (Welch & Albertsen, 2009). In Europe, the estimated cost of overdiagnosis 
and overtreatment amounts to 39% of the total cost of screening and treatment. This 
results in over €23 million ($33 million) spent on screening and treatment of patients that 
do not benefit from the screening or the treatments (Heijnsdijk et al., 2009). In the U.S., 
the amount of money spent as a result of overtreatment of PCa was estimated to be 
around $32 million per annum, which is comparable to the estimate in Europe (Aizer et 
al., 2013). 
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Beyond the tangible costs of PSA screening leading to false positives, 
overdiagnosis, and overtreatment, there are also intangible costs of PSA screening. 
Namely, negative psychological effects on patients and their family members as a result 
of a positive PSA screening result. It has been found up to 49% of the patients who have 
had a positive screening outcome that ultimately resulted in a benign biopsy reported 
thinking about PCa more than a control group that had a normal PSA test result (Ford et 
al., 2005). These patients have a higher perceived risk of PCa and have reported problems 
with sexual function for up to a year (Moyer, 2012). Also, it has been reported that 
patients are less likely to return to be screened again after a false-positive result. This 
Table 2 – Costs of Treatment for Prostate 
Adenocarcinomas*: 
Low 
Risk 
Moderate Risk High Risk 
Radiation 
Procedures 
External Beam Radiation 
Therapy + Brachytherapy 
$40,588 $43,566 $50,276 
Brachytherapy  $25,067 $32,553 $43,952 
3D Conformal Radiation 
Therapy 
$27,626 $30,838 $42,397 
Intensity-Modulated 
Radiation Therapy 
$37,718 $44,639 $53,539 
Surgical 
Procedures 
Open Radical Prostatectomy $20,245 $28,589 $36,279 
Robot-Assisted Radical 
Prostatectomy 
$19,901 $28,017 $35,014 
Laparoscopic Radical 
Prostatectomy 
$20,497 $29,041 $35,118 
*This table lays out the costs of various procedures that are used in the treatment for PCa. Depending on 
the assessed risk level of the patients, different treatment modalities are employed. Low risk to moderate 
risk patients are preferentially treated with surgical procedures while those of higher risk are preferentially 
treated with radiation. Because of possible overdiagnosis and overtreatment due to PSA screening, a lot of 
costs associated with the treatment of PCa using these procedures do not confer benefits to a vast majority 
of the patients treated. 
Table adapted from: Cooperberg, M. R., Ramakrishna, N. R., Duff, S. B., Hughes, K. E., Sadownik, S., 
Smith, J. A., & Tewari, A. K. (2013). Primary treatments for clinically localized prostate cancer: a 
comprehensive lifetime cost-utility analysis. BJU International, 111(3), 437–450. doi:10.1111/j.1464-
410X.2012.11597.x 
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could result in the failure to diagnose PCa that may develop and progress to more 
advanced stages leading to higher costs for treatments and more adverse physical 
consequences (Ford et al., 2005). 
F. Current Recommendations for PSA testing: 
As a result of the disadvantages discussed earlier, many large American medical 
organizations currently caution the use of PSA screening in men. Recanting on its 2008 
recommendation of screening on in men between 45 and 75 years old, the USPSTF now 
recommends against PSA screening in men of all ages (Moyer, 2012). The American 
Academy of Family Physicians follows in the USPSTF’s footstep in recommending 
against the use of PSA-based screening in all age groups (“Prostate Cancer -- Clinical 
Recommendations -- AAFP,” 2014).  
Other organizations are less absolute in their recommendations. The American 
Urological Association (AUA) recommends PSA screening in men older than 40 only if 
the patients request to be screened (Carter et al., 2013). In such cases, the doctor and 
patient need to discuss the benefits and the harms related to screening. The ACS 
recommends informed decision making when it comes to PCa screening and men with 
average risk should be presented with the relevant information at 50 (Wolf et al., 2010). 
The American College of Preventative Medicine’s (ACPM) recommendation is similar to 
that of the ACS. The ACPM concludes that there is insufficient evidence that PSA-based 
screening supported by DRE to recommend routine screening. It advises informed 
decision making between doctors and patients when determining the need for PSA 
screening (Lim, Sherin, & ACPM Prevention Practice Committee, 2008). The American 
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College of Physicians states that men between the age of 50 and 69 years should be 
informed for the limitations of the PSA-based screening test for PCa and recommends 
against screening in average-risk men below the age of 50, above the age of 69, or have a 
life expectancy of less than 10-15 years (Qaseem et al.,  2013). 
 22 
PUBLISHED STUDIES 
 
While PSA-based screening test was a great first step in detecting PCa early, the 
test is limited by a number of considerable drawbacks and the true benefits incurred by its 
use are uncertain. It is also important to realize that while PSA is a prostate-specific 
marker, it is not PCa-specific and can be elevated during a whole host of other non-
neoplastic diseases. From previous studies, it can be concluded that the test alone is 
considered inadequate in the early screening and detection of PCa. This conclusion is 
supported by the recommendations of various national organizations that caution 
physicians in the use of PSA test or outright recommend against it. However, despite 
these recommendations, PCa remains one of the most prevalent cancers affecting older 
American men. As a result, there is a need to either improve upon the PSA-based 
screening or to find alternatives for screening for PCa.  
I. Comparing PSA Alternatives - Receiver Operating Characteristic and 
Area Under the Curve: 
In order to assess the ability to predict clinically relevant PCa of different PSA-
derived screening methods, one needs a way to compare the ability for a specific test to 
predict the presence of PCa with those of other screening methods. A receiver operating 
characteristics (ROC) graph is the best way to achieve this as it assesses a screening test’s 
ability to differentiate between normal conditions and abnormal conditions. A ROC curve 
plots the sensitivity (true positive rate) vs 1-specificity (false positive rate) of a particular 
screening test (Figure 7). The area under the curve (AUC) is then calculated to measure 
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the accuracy of the screening test. An AUC of 1.0 represents a perfect test that can 
differentiate between normal and abnormal conditions every time. An AUC of 0.5 
represents a worthless test, one that has as good of a chance at predicting disease 
presence as random chance. In essence, AUC measures the probability that a screen test 
will rank a randomly chosen positive test higher than a randomly chosen negative test 
(Thomas G. Tape, n.d.). It also shows the tradeoff between the sensitivity and the 
specificity of a particular test. As it takes all possible sensitivity and specificities 
combinations into account, possible optimal cutoff points can be deduced for specific 
tests. These factors make ROC curves and the AUC values the ideal statistic for 
interpreting the accuracy of various PCa screening tests. 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Sample Receiver Operating Characteristics Curves: 
The three curves depicted in this figure demonstrates what is considered excellent, good, or worthless tests. 
As the curve approaches a true positive rate of 1 and a false positive rate of 0, its area-under-the-curve 
(AUC) increases and the performance of the test increases. A large AUC is indicative of a good test. The 
maximum AUC value attainable is 1. 
Figure taken from: Thomas G. Tape. (n.d.). Plotting and Intrepretating an ROC Curve. Interpreting 
Diagnostic Tests. Retrieved May 7, 2014, from http://gim.unmc.edu/dxtests/roc2.htm 
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Another statistic that is frequently used in the assessment of a test’s performance 
is the positive predictive value (PPV). PPV is the fraction of positive results of screening 
tests that are true positive results: 
𝑃𝑃𝑉 =  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
 
While this may seem like an attractive test to use in the assessment and comparison of 
various screening methods, it is actually not as accurate as AUC in assessing performance 
of various tests. This is due to the fact that PPV is not an intrinsic statistic in tests and is 
heavily influenced by the prevalence of the disease in the test population that is being 
screened ( Lengerich, 2014). As such, varying conditions and test parameters can result in 
different PPV values. Because of the heterogeneous nature of PCa, the AUC value 
obtained from ROC analysis is a more attractive statistic to use when comparing different 
screening methods because it is not influenced by the different prevalence of the disease 
in different study cohorts across various studies and is a stable characteristic. 
II. PSA-derived Alternative Screening Methods: 
Currently, there are multiple avenues being investigated for improving PSA-based 
screening methods. These methods include proposing alternative PSA cutoff ranges, 
measuring free-to-total PSA (also known as %fPSA), proPSA, PSA density, PSA 
velocity, PSA acceleration, and PSA doubling time. Out of these various methods to 
improve upon the traditional PSA test, alternative PSA cutoff ranges, %fPSA, and 
proPSA are the most promising avenues for improving the PSA screening test. 
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A. Establishing an Early Warning PSA Zone: 
As previously mentioned, although the currently accepted upper bound for normal 
PSA levels is 4.0 ng/ml, this cutoff has been shown to miss potentially life-threatening 
cancers that have lower PSA levels (Thompson et al., 2004). This presents a conundrum 
when considering the use of PSA screening to screen for PCa. If the cutoff level is 
lowered below 4.0 ng/ml, the sensitivity of the test is increased at the risk of decreasing 
the specificity of the test. This could result in an increase in the amount of false-positives 
that lead to a surge of overdiagnosis and overtreatment that would in turn result in 
considerable harm to patients who otherwise have indolent tumors or noncancerous 
prostate conditions. This presents a fundamental flaw in the screening test in that it is 
extremely difficult to determine the aggressiveness of the cancer purely relying on the 
PSA test.  
Instead of using the classical cutoff of 4.0 ng/ml and beginning screening at 
around age 50, some researchers advocate for the establishment of an Early-Warning 
PSA (EWP) zone between 1.5 ng/ml to 4.0 ng/ml for a patient’s first test at the age of 45 
(Crawford et al., 2011). Crawford et al.’s (2011) reasoning behind this change is that the 
baseline PSA value measured at an earlier age may have some predictive value that can 
be used to predict the development of PCa and be used to stratify patients into different 
risk categories. In essence, by decreasing the age and the baseline PSA threshold, a new 
risk stratification strategy is introduced that relies on the predictive value of the baseline 
PSA value (Crawford et al., 2011). It has been demonstrated that Caucasian men with a 
baseline of greater than 1.5 ng/ml PSA levels develop a 15-fold increase in PCa risk over 
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men who have lower baseline levels for their initial PSA screening result. This risk is 
increased 19-fold in black men. When assessed with ROC analysis, it was found that 
using EWP zone to predict future diagnosis of cancer within 4 years of the test results in 
an AUC value of 0.87 (Crawford et al., 2011). The AUC values for a standard PSA 
screening test across all PSA levels range from 0.50-0.66 (Filella & Giménez, 2012). The 
high AUC value of using EWP zone compared to traditional PSA suggests that the 
establishment of a baseline EWP zone can be a more powerful tool than simply screening 
using the 4.0 ng/ml cutoff.                                                                                                                                                                                                                                                                                                                                                                                                                                                
A recent study conducted by Vertosick et al. takes this concept of EWP zones 
further. The researchers suggest that EWP zones are a better predictor for the risk of 
developing PCa than race or family history (Vertosick et al.,  2014). According to a study 
conducted by Vickers et al. in 2013, it was determined that around 44% of PCa deaths by 
the age of 75 were in men who had a higher baseline PSA level of greater than or equal to 
1.6 ng/ml at ages between 45 and 49 (Vickers et al., 2013). Vertosick et al. (2014) 
determined that patients with family history represent 25% of PCa deaths and that 
patients of Black descent represented 28% of PCa deaths. Thus, they argue that EWP 
zones offer better risk stratification than relying on race and family history and can be 
used to determine patients who need more frequent and earlier screening. 
Regardless of the advantages shown by Crawford et al. and Vertosick et al., 
lowering PSA cutoff ranges could result in an increase in overdiagnosis, overtreatment, 
and medical financial burden for patients and the US healthcare system. In order to 
combat this potential issue, Crawford et al. (2011) suggest that men with lower baseline 
 27 
PSA levels be screened less frequently than men with higher baseline PSA levels. The 
researchers argue that by targeting high risk individuals identified by the EWP zones, the 
total number of PSA tests conducted in the US can be reduced as much as 70% and save 
around $1 billion annually (Crawford et al., 2011). However, even with these assurances, 
the true effect of using EWP zones have yet to be tested and while this change to PSA 
screening seems promising, more studies are needed to determine its true effectiveness. 
B. Free-to-total PSA: 
Another promising improvement to the traditional serum PSA screening test is the 
measurement of free-to-total PSA (%fPSA) in addition to traditional PSA measurements. 
As the name suggests, %fPSA is a simple ratio between the measured levels of free PSA 
divided by the total serum PSA. The basis for using %fPSA is the fact that not all PSA 
molecules are free in the serum. Of the total PSA levels, around 70% are bound to the 
protease inhibitor α1-antichymotrypsin while the other 30% are free (Roddam et al., 
2005). In men with PCa, the level of %fPSA is lower than those who do not have PCa ( 
Lee et al., 2006). As a stand-alone test, %fPSA performs comparably to using the 
traditional PCa screening test measuring total serum PSA. According to a meta-analysis 
that analyzed the performance of %fPSA, as an independent test %fPSA has an ROC 
AUC value of 0.70 across all PSA levels ( Lee et al., 2006). Comparatively, the AUC of 
PSA has a range from 0.50 to 0.66 (Filella & Giménez, 2012).  
The usefulness of %fPSA comes in when it is being used as a reflex test. A reflex 
test is used as a confirmatory test when measured serum PSA levels are within the 4.0 
ng/ml to 10 ng/ml, a range that is considered a diagnostic gray zone ( Lee et al., 2006). It 
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is relatively difficult to definitively say whether a patient has PCa when his PSA levels 
fall into this range due to the fact that other prostate diseases can raise serum PSA to this 
level even in the absence of PCa. Since BPH and prostatitis have been shown to increase 
PSA levels but not change %fPSA, the difference in %fPSA levels allows for 
differentiation between the cancerous and noncancerous conditions in men who have 
borderline levels of serum PSA (Lee et al.,  2011). This increases the accuracy of the 
PSA blood screening and can help avoid unnecessary biopsies.  
%fPSA has also been suggested to be useful in circumstances when serum levels 
fall below 4.0 ng/ml. Although it is relatively rare for patients to develop PCa with PSA 
levels lower than 4.0 ng/ml, the PCPT has shown that there is no definite PSA level 
below which one can definitively say there is an absence of PCa (Thompson et al., 2004). 
In a study conducted in Brazil, it was demonstrated that the PPV of %fPSA in finding 
PCa in situations where PSA levels were less than 4.0 ng/ml was around 26.4% at 
%fPSA levels ≤15% (Faria et al., 2012). This finding suggests %fPSA’s usefulness in 
detecting PCa in PSA levels below 4.0 ng/ml.  
These studies suggest %fPSA as a viable companion to the traditional serum PSA 
test that increases the overall performance of PSA screening. However, the test is not 
without its disadvantages.  One of the major difficulties facing physicians when using 
%fPSA as a tool for PCa screening is that it is currently unknown what the optimal cutoff 
point is. Previous studies have suggested various cutoff points that correspond with 
various levels of serum PSA levels that range from 10% to 25% (Catalona et al., 1998; 
Lee et al., 2011). As a result, there is currently no standardized cutoff point for %fPSA 
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use in PCa screening. In addition, as screening tests dip into PSA levels below 4.0 ng/ml, 
it is necessary to take into account the increased probability of overdiagnosis. Thus, 
although %fPSA seem to be able at detecting PCa at lower PSA levels, it is unknown 
whether %fPSA can differentiate between cancers of differing stages and aggressiveness 
accurately enough to be a viable screening tests for PCa at lower PSA ranges.  
There have been efforts to help determine the optimal %fPSA level. One idea 
behind improving %fPSA is the use of a classification system based on genetics to 
enhance the clinical performance of %fPSA used alongside traditional PSA serum tests. 
It is argued that variability with serum PSA levels depend on genetic polymorphisms of 
certain genes. Zambon et al. (2012) tested this idea for the first time. The authors 
suggested that KLK3 polymorphisms could be a target for genetic categorization to 
enhance %fPSA performance (Zambon et al., 2012). The KLK3 gene encodes for PSA 
and has been previously implicated in changing serum PSA levels. The authors tested 
various different polymorphisms that included three SNPs in the promoter region and one 
polymorphism at the 3’ boundary of the KLK3 locus. It was found that the 
polymorphisms had statistically significant effects on the %fPSA level only and not on 
measured total serum PSA level in the context of screening for PCa (Zambon et al., 
2012). Of the four groups that varied genetically, two groups had the optimal %fPSA 
cutoff of 11% while the other two groups had the optimal cutoff of 14.5% (Zambon et al., 
2012). Since lower %fPSA levels were shown to correlate with a higher risk for PCa, it 
was reasonable to conclude that patients with less than 11% %fPSA be considered for 
further screening while those above 14.5% be considered negative for PCa. Those men 
 30 
who fall within the 11%-14.5% range can then be genetically assessed to determine 
whether to undergo further testing based on the results (Zambon et al., 2012). While this 
result from Zambon et al. (2012) is encouraging, it is the first study to try to determine 
%fPSA cutoff points using genetic testing. More research will need to be conducted 
before the optimal cutoff point can be determined. 
C. PSA Proenzymes: 
Despite limitations of using %fPSA in screening for PCa, more recently it has 
been found that fPSA is actually comprised of various isoforms of PSA. These isoforms 
include Benign PSA (BPSA), intact PSA (iPSA), and proPSA (Le et al., 2010). These 
isoform show great promise for use in the screening for PCa. It has been shown 
previously that BPSA and iPSA are associated with noncancerous prostate conditions 
while proPSA is associated with PCa (Le et al., 2010). This finding exhibits the potential 
for using proPSA as a biomarker for screening for PCa. One of the main issues that 
plagued traditional PSA screening was that PSA was prostate-specific and not PCa-
specific. As a result, it was sometimes difficult to differentiate between noncancerous 
prostate conditions like BPH and prostatitis with PSA screening alone. It was found by 
Heidegger et al. (2014) that [-2]proPSA levels, a proPSA isoform, was significantly 
higher in cancerous prostates than in benign prostates 4 years prior to PCa diagnosis 
(Heidegger et al., 2014). The introduction of a PCa specific biomarker that can 
distinguish between noncancerous and malignant prostate conditions addresses one of the 
greatest drawbacks of PSA screening: the inability to differentiate between PCa and BPH 
or prostatitis based on PSA levels alone. 
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ProPSA is found in three different forms and these vary by the length of the pro-
leader peptide. Cleaved by kallikrein 2 and trypsin, [-7]proPSA yields active PSA. The 
other forms are [-5, -7]proPSA, [-4]proPSA, and [-2]proPSA (Le et al., 2010). Of all 
these different isoforms of proPSA, [-2]proPSA has been implicated in PCa. Upon 
histological staining of prostate tissue, [-2]proPSA was shown to be preferentially 
concentrated in PCa tissue (Figure 8) (Chan et al., 2003). Consequently, [-2]proPSA is 
regarded as a promising marker for PCa as it can help physicians identify PCa tissues 
even in presence of BPH or prostatitis.  
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In a multitude of multicenter trials, it has been shown that %[-2]proPSA can be 
used as a screening measure for PCa. %[-2]proPSA is calculated using the following 
equation: 
(
[−2]𝑝𝑟𝑜𝑃𝑆𝐴
𝑓𝑃𝑆𝐴
× 100) 
Figure 8 – Immunohistochemical Staining of [-2]proPSA in PCa Tissue:  
Staining of PCa tissue using monoclonal antibody against [-2]proPSA. The preferential staining of PCa 
tissue for [-2]proPSA can be seen on the left of the figure. Normal prostate tissue does not stain for [-
2]proPSA. 
Figure taken from: Chan, T. Y., Mikolajczyk, S. D., Lecksell, K., Shue, M. J., Rittenhouse, H. G., Partin, 
A. W., & Epstein, J. I. (2003). Immunohistochemical staining of prostate cancer with monoclonal 
antibodies to the precursor of prostate-specific antigen. Urology, 62(1), 177–181. doi:10.1016/S0090-
4295(03)00138-9 
 33 
In a meta-analysis, the performance of %[-2]proPSA had an AUC of 0.64-0.78 (Filella & 
Giménez, 2012). AUC values for a traditional PSA test range from 0.50-0.66 (Filella & 
Giménez, 2012). Although the range of AUC values for %[-2]proPSA suggests that %[-
2]proPSA outstrips PSA screening alone in testing for PCa, it is debated whether %[-
2]proPSA outperforms %fPSA. A study conducted by Loeb et al. showed that %[-
2]proPSA significantly outperformed %fPSA (p<0.005) while Lazzeri et al. found that 
although %[-2]proPSA had a higher AUC value, it did not significantly outperform 
%fPSA (p>0.300) (Lazzeri et al., 2013; Loeb et al., 2013). A similar result by Sokoll et 
al. substantiates Lazzeri et al.’s finding (Sokoll et al., 2008). This difference could be due 
the heterogeneous nature of the tests performed and the population of the test cohort 
(Filella & Giménez, 2012).  
Based on these results, a new test called the Prostate Health Index (PHI) was 
developed by the company Beckman Coulter and was recently approved by the FDA in 
2012 for use to screen for PCa. The PHI is calculated using the following equation: 
%[−2]𝑝𝑟𝑜𝑃𝑆𝐴 × √𝑃𝑆𝐴 
The PHI has very similar AUC levels compared to %[-2]proPSA (0.67 to 0.77 and 0.64 
to 0.78 respectively) but also takes into account of the total serum PSA levels (Filella & 
Giménez, 2012).  The PHI test employs a blood test that is simple to conduct and is ideal 
for a clinical screening situation. 
In addition to the promising predictive nature of %[-2]proPSA for PCa, absolute 
values of [-2]proPSA is also potentially useful in PCa screening tests. The absolute levels 
of [-2]proPSA was shown to not be an effective predictor for PCa by itself with. In a 
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study conducted by Lazzeri et al. (2013), the AUC of the ROC curve for absolute levels 
of [-2]proPSA was 0.51, which confers no useful screening information. A similar result 
was also found by Catalona et al. who found the AUC levels to be 0.56 ( Catalona et al., 
2011). Despite these findings, absolute values of [-2]proPSA could be useful in 
determining the aggressiveness of the cancer detected, a previously difficult issue to 
resolve based on screening alone. Heidegger et al. (2014) found that absolute levels of [-
2]proPSA was associated with the GS of PCa. In this study, it was found that highly 
aggressive cancers with a GS≥8 could be distinguished from moderately aggressive 
cancers with a GS≤7 three years prior to PCa diagnosis via biopsy using absolute levels 
of [-2]proPSA (Heidegger et al., 2014). The [-2]proPSA values were significantly higher 
(p<0.001) for cancers classified as GS≥8 than those classified as GS≤7 as early as 3 years 
prior to diagnosis (Figure 9) (Heidegger et al., 2014). Heidegger et al.’s (2014) findings 
also suggested that [-2]proPSA was better than PSA alone in predicting the GS of PCa up 
to 4 years prior to diagnosis (Table 3). 
Table 3 – The Ability of [-2]proPSA to Predict GS of PCa*: 
Years before PCa diagnosis AUC of [-2]proPSA AUC of 
PSA 
4 years 0.80 0.61 
3 years 0.78 0.55 
2 years 0.74 0.60 
1 years 0.85 0.53 
*Absolute levels of [-2]proPSA has higher AUC levels when used to predict GS of PCa diagnosed via biopsy 
compared to that of just using PSA. This suggests that absolute [-2]proPSA can be used to differentiate 
between PCa of different aggressiveness. 
Table adapted from: Heidegger, I., Klocker, H., Steiner, E., Skradski, V., Ladurner, M., Pichler, R., … 
Bektic, J. (2014). [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer and 
Prostatic Diseases, 17(1), 70–74. doi:10.1038/pcan.2013.50 
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Furthermore, [-2]proPSA levels can be used to distinguish between organ-
confined PCa and non-organ-confined PCa. Organ-confined PCa is not as detrimental to 
the patient compared to non-organ-confined disease. As early as 4 years prior to 
diagnosis, there was a significant increase in [-2]proPSA for non-organ-confined PCa 
compared to the levels in organ-confined PCa (Heidegger et al., 2014). As such, absolute 
levels of [-2]proPSA can be extremely useful when screening for PCa in that it can help 
physicians identify aggressive cancers from those that are more unlikely to harm the 
patient. This can decrease the amount of overdiagnosis and overtreatment of patients 
who, instead of undergoing invasive procedures that can cause considerable harm to the 
patients, can be carefully observed to assess the risk level of indolent PCa cases. 
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One distinct disadvantage to the PHI test is that it is more costly to perform and is 
currently not covered by health insurance like Medicare. Based on the estimates from 
Beckman Coulter and Medicare Fee Schedule, one PHI test costs approximately $71.95 
while PSA combined with %fPSA costs $53.70 (Nichol et al., 2012). However, in a study 
funded by Beckman Coulter, Nichol et al. (2012) argued that despite the higher costs, the 
overall screening for PCa could cost less when using PHI compared to PSA-fPSA 
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Figure 9 – [-2]proPSA  Differentiation Between PCa of Different GS: 
[-2]proPSA has the ability to differentiate between high GS PCa from moderate GS PCa up to 3 years prior 
to PCa diagnosis with biopsy. 
Figure taken from: Heidegger, I., Klocker, H., Steiner, E., Skradski, V., Ladurner, M., Pichler, R., … Bektic, 
J. (2014). [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer and Prostatic 
Diseases, 17(1), 70–74. doi:10.1038/pcan.2013.50 
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combination through a reduction in overdiagnosis and overtreatment. While this claim 
may hold some validity, it still needs to be verified via independent studies. 
Regardless of the promise of the [-2]proPSA biomarker for use in PCa screening, 
one must understand that the test is not perfect. Due to its relatively recent introduction as 
a test compared to PSA, the cutoff points for normal %[-2]proPSA and PHI levels are 
still debated (Filella & Giménez, 2012). Although approved by the FDA, its effectiveness 
over PSA at curbing overdiagnosis and overtreatment is still uncertain despite promising 
results from previous studies. With all these caveats in mind, the [-2]proPSA biomarker 
and its derivative index, PHI, are still promising avenues to improve the traditional PSA 
serum screening test due to its ability to not only improve upon PSA’s ability to predict 
the presence of PCa but also potentially differentiate between different grades of PCa. 
III. PCa Screening Methods Beyond PSA: 
As a result of the lack of agreement in the efficacy of the PSA test within the 
scientific literature, in addition to possibly improving PSA screens, there has been an 
interest in finding alternative screening methods for PCa. The recent literature highlights 
various possible avenues for pursuing new screening methods that offer alternatives to 
PSA screening. These alternative avenues include the screening for PCa with epigenetic 
markers and biomarkers present in urine. 
A. Epigenetic markers for use in PCa screening: 
Epigenetics involve the investigation of the meiotically and mitotically heritable 
changes in gene activity that occur independently of the changes in an organism’s 
primary DNA sequence (Choi et al., 2013). These changes include histone modifications 
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and DNA hyper- and hypo-methylation. All of these epigenetic modifications have been 
found to occur in cancer. However, of these three different types of epigenetic changes, 
DNA hypermethylation is best characterized in various types of cancers including PCa 
(Costa et al., 2007). DNA hypermethylation primarily occurs in mammals at cytosines 
within sequences of repeating cytosine and guanine nucleotides (Jerónimo et al., 2011). 
These repeating C and G sequences are called CpG islands and are frequently found in 
the 5’ regulatory regions of genes  (Jerónimo et al., 2011). The methylation process is 
carried out by DNA methyltransferases (DNMTs) that add methyl groups to the fifth 
carbon of the cytosine residue ring and it has been shown that genes that are silenced 
often have hypermethylated CpG islands (Choi et al., 2013). The mechanisms through 
which methylated CpG islands silence genes range from preventing the binding of 
regulatory factors to affecting chromatin structure. 
There are two distinct types of DNA methylations that occur during the course of 
a person’s life (Figure 10). One that is passed on during cell division and is passed down 
from one generation of cells to their daughter cells called maintenance methylation. As its 
name suggests, this type of DNA methylation maintains the DNA methylation profile of 
cells during cell division in order to maintain the cells’ specific function (Jones & Liang, 
2009). The other type of methylation is where new methyl groups are introduced into 
CpG islands of genes by DNMTs via de novo methylation. The type of epigenetic change 
that occurs throughout development, aging, and in carcinogenesis are de novo 
methylation changes (Henrique & Jerónimo, 2004). Often times, the methylation 
silencing in cancer cells affects genes involved in key cellular processes that when 
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disrupted, can cause progression into cancer cells. 
 
Methylation changes are found via methylation-specific PCR (MSP) techniques 
that utilizes bisulfite-treated DNA. The use of bisulfite converts any unmethylated 
cytosine residues into uracil while keeping 5-methylcytosine residues unaffected. The 
DNA can then be probed with two sets of primers that are designed to amplify 
Figure 10 – Maintenance Methylation Versus de novo Methylation: 
Cytosine methylation in the promoter regions is a regulatory mechanism that is employed by cells. Cytosine 
methylation occurs on cytosine residues within CpG islands and fall into two categories: De novo 
methylation or maintenance methylation. Maintenance methylation occurs during cell division that 
maintains methylation patterns of genes while de novo methylation occurs on cytosine molecules that were 
not previously methylated. Both types of methylation are carried out by DNA methyltransferases. 
Figure adapted from: Ben Huang. (2007, July 27). Epigenetics. UCSF School of Medicine: Genes and 
Genomes Online Learning Module. Retrieved May 12, 2014, from 
http://missinglink.ucsf.edu/lm/genes_and_genomes/methylation.html 
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methylated or unmethylated sequences of the DNA (Henrique & Jerónimo, 2004). This 
result is then run on a gel in the conventional MSP (CMSP). The results from CMSP can 
only determine if the DNA section in question is methylated but not the extent of the 
methylation. In order to measure the extent of the methylation, a real-time quantitative 
MSP can used. In this case, the DNA is amplified with two sets of primers while a 
fluorescent probe that can anneal to methylated sections are used to measure the extent of 
the methylation by comparing to reference genes such as MyoD1 or β-actin (Henrique & 
Jerónimo, 2004). 
A relatively new field compared to the study of PSA, the study of PCa epigenetics 
has resulted in a number of promising epigenetic biomarkers that can be used in 
screening for PCa in the future. Of the more than 50 common aberrant DNA 
hypermathylation changes, three genes show particular promise in being used for PCa 
screening: GSTP1, APC and PTGS2. 
1. Glutathion-s-transferase P1 gene: 
GSTP1 encodes the glutathione-s-transferase P1 enzyme (GSTP1) that is part of a 
family of enzymes that protecst DNA from carcinogens and reactive oxygen species by 
conjugating glutathione to these species (Henrique & Jerónimo, 2004). It is a caretaker 
gene that acts to protect the prostate from insults that could result in carcinogenesis. Loss 
of function of GSTP1 could result in the predisposition of prostate cells for DNA damage 
(Phé et al.,  2010). In PCa, loss of expression of GSTP1 was found and is the result of the 
silencing of its gene through promoter hypermethylation. This is one of the most PCa-
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specific epigenetic changes because it is seldom found in BPH and other urogenitary 
cancers (Henrique & Jerónimo, 2004).  
In one study conducted on tissue samples of patients with PCa, it was found that 
GSTP1 promoter hypermethylation could accurately predict the presence of PCa. In PCa 
tissue samples, more than 90% had GSTP1 promoter methylation (Nelson et al., 2013). In 
a ROC analysis using tissue samples, it was found that GSTP1 hypermethylation had an 
AUC value of close to 0.96 with high sensitivity (90.6%) and specificity (100%) 
exhibiting its high predictive ability for PCa (Bastian et al., 2005). There have been a 
multitude of other studies that were also conducted on tissue samples that have shown 
that GSTP1 hypermethylation exhibits high sensitivity and specificity for detecting PCa 
(Van Neste et al., 2012).  
One of the reasons that GSTP1 hypermethylation is one of the ideal epigenetic 
targets for PCa screening is that it can be detected in bodily fluids such as blood serum 
and urine. Like PSA, this characteristic lends itself to the easy acquisition of samples 
during routine physical exams. In one study conducted by Goessl et al. (2001), the 
researchers have measured GSTP1 promoter hypermethylation in the urine of 78% of the 
patients who were diagnosed with locally advanced or metastatic disease, 68% in the 
urine of patients with early PCa. Furthermore, GSTP1 promoter hypermethylation was 
detected in 72% of the plasma samples of patients being treated for PCa (Goessl et al., 
2000). In the light of this finding, it is important to note that the results obtained by 
Bastian et al. (2005) and those included in Van Neste et al.’s (2012) study were from 
tissue samples of a previously diagnosed prostate that is positive for PCa. In fact, 
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although GSTP1 detected in urine has a specificity (86.8-100%), it has a low sensitivity 
(18.8-38.9%). As such, the same conclusion from tissue samples may not apply to GSTP1 
promoter methylation detection in urine and/or blood samples, samples that are more 
desirable for a screening scenario. Further research will need to be conducted in order to 
assess the viability of using urine or blood serum to measure GSTP1 promoter 
hypermethylation as a screening test for PCa. 
2. Adenomatosis polyposis coli gene 
In addition to GSTP1, APC, which encodes the tumor suppressor adenomatosis 
polyposis coli (APC), shows promise as a possible epigenetic biomarker for PCa. First 
implicated in colorectal cancer, APC has also been shown to be inactivated in PCa 
through methylation (Bastian et al., 2005). Similar to GSTP1, when analyzed with ROC, 
the AUC value was 0.90 (Bastian et al., 2005). This points to the predictive value of APC 
promoter methylation in detecting PCa. However, unlike GSTP1, since APC promoter 
methylation is not specific for PCa but is also present in other cancers, its sensitivity 
(83%) and specificity (92.9%) were lower than that of GSTP1 (Bastian et al., 2005). 
Despite this, an important fact is that APC promoter methylation is not detected in 
conditions like BPH (Bastian et al., 2005). As such, it still potentially has value to be 
used in PCa screening. 
Since this result with APC methylation was obtained via tissue samples, it does 
not guarantee that the same result will be found in urine or serum samples that are 
preferred for screening test due to their minimally invasive nature. However, it has been 
previously described that APC promoter methylation have been detected in urine samples 
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so its application in screening tests cannot be completely ruled out (Jerónimo et al., 
2011). Like GSTP1, further research will need to be conducted in order to definitively 
ascertain whether the DNA hypermethylation changes in APC promoter regions as a 
result of PCa can be a viable biomarker for use in PCa screening. 
3. Prostaglandin-endoperoxide synthase 2 gene 
The last gene that has shown potential to be used in PCa screening is the PTGS2 
gene that encodes prostaglandin-endoperoxide synthase 2 (PTGS2). PTGS2 has been 
implicated in various cellular responses that include regulation of inflammation and 
carcinogenesis (Bastian et al., 2005). Similar to both GSTP1 and APC, the AUC value for 
PTGS2 was 0.91 with a sensitivity of 71.7% and a specificity of 100% (Bastian et al., 
2005). Like the other two promising genes, PTGS2 promoter methylation only occurs in 
PCa and not noncancerous prostate conditions, lending itself potentially useful in 
discriminating between the conditions so as to avoid misdiagnosis leading to 
overtreatment (Bastian et al., 2005). 
Although PTGS2 promoter hypermethylation shows potential for predicting PCa 
in tissue samples, it has not been reported to be detectable in urine or serum samples. As 
such, despite its high AUC value, PTGS2 may be limited in its clinical value in the early 
detection of PCa through minimally invasive procedures. Future investigations into 
whether PTGS2 can be detected in urine or serum samples will elucidate whether this 
particular epigenetic marker can be used in screening tests for PCa. 
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B. Non-epigenetic Urine Biomarkers: 
Other than epigenetic alterations, other biomarkers detected in urine can be used 
for PCa screening. Biomarkers that are PCa specific and can be detected in urine make 
for promising PCa screening targets because of the ease in obtaining samples for analysis 
without the use of invasive procedures that may cause stress or harm to patients. These 
types of biomarkers include non-coding RNA, gene fusion transcripts, and proteins.  
1. Non-Coding RNA: Prostate Cancer Antigen 3 
Prostate Cancer Antigen 3 (PCA3) was first described in 1999. It is a prostate-
specific non-coding RNA from chromosome 9q22-21 that is highly overexpressed in PCa 
tissues (Challacombe et al.,  2013). Compared to non-neoplastic prostate tissue, PCA3 
expression is increased by 66 fold in 95% of PCa tissues (Crawford et al., 2012). This 
piqued the interests of researchers searching for possible PCa-specific biomarkers that 
can be used in PCa screening efforts that can exclude conditions such as BPH. 
PCA3 is measured using samples of whole urine from patients after undergoing 
DRE. It is important for patients to undergo DRE prior to urine collection as the prostate 
massage from DRE results in the shedding of cells from the prostate into the urine that 
can be collected to detect PCA3 levels (Chevli et al., 2014). This characteristic of PCA3 
makes it a highly viable target as a possible urine biomarker for PCa screening as it does 
not require invasive procedures like previously reported epigenetic markers. After the 
sample has been collected, a real-time polymerase chain reaction called Progensa® PCA3 
is used quantify PCA3. A PCA3 score is generated by establishing a ratio between PCA3 
and PSA mRNA (Crawford et al., 2012): 
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Currently, the FDA approved cutoff point for the PCA3 score is 25 (Crawford et 
al., 2012). A score above 25 means that there is an increased probability for a biopsy 
positive for PCa and vice versa for a score below 25. This cutoff point is still being 
debated as studies have argued that a cutoff of 35 offers better balance between test 
sensitivity and specificity (Challacombe et al., 2013; Chevli et al., 2014; Crawford et al., 
2012). 
PCA3’s predictive potential for PCa has been studied in great detail. In multiple 
studies, it has been shown through ROC analysis that the AUC value for PCA3 tests 
significantly outperform that of the traditional PSA screening test. PCA3 tests had an 
estimated AUC of 0.70-0.74 compared to that of the PSA test value of 0.50-0.66 (Chevli 
et al., 2014; Crawford et al., 2012; Ferro et al., 2013; Filella & Giménez, 2012; Stephan 
et al., 2013). 
Disadvantages of PCA3 use in the screening of PCa include the cost of the test 
and the discomfort for patients. Compared to the traditional PSA test or even the PHI test, 
the Progensa® PCA3 test is more expensive. Although there are no data for cost in the 
US, the test costs $385.00 CAD in Canada (“Cost of the Test : PCA3 Urine Test for 
Prostate Cancer Detection,” 2013). Comparatively, the PSA test costs $30 CAD which is 
comparable to the costs in the US (Sher, 2012). Additionally, the DRE needed in order to 
collect urine samples may cause discomfort for patients compared to the standard blood 
tests and adds a layer of complexity to the screening procedure. One final caveat 
regarding the use of Progensa® PCA3 is that although it is currently approved by the 
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FDA, it is only approved for use in patients that have had one or more negative biopsies 
and is not approved for use with patients that have yet to undergo an initial biopsy 
(Stephan et al., 2013). 
2. Gene Fusion Transcripts: TMPRSS2-ERG 
Currently, the majority of research efforts in detecting fusion transcript 
biomarkers in urine is focused on the feasibility of using TMPRSS2:ERG fusion to help 
detect PCa presence in urine. TMPRSS2:ERG is a gene fusion between an androgen-
regulated transmembrane-serine protease 2 (TMPRSS2) gene and the Erythroblast 
Transformation-Specific-related gene (ERG). Described in 2005 by Tomlins et al., 
TMPRSS2:ERG fusion transcripts were found in 50% of PCa (Tomlins et al., 2005). By 
itself, TMPRSS2 codes for a prostate-specific, androgen-responsive transmembrane serine 
protease (St. John et al., ). ERG is part of the Erythroblast Transformation-Specific 
family of genes that are responsible for regulating embryonic development, cell 
proliferation, differentiation, angiogenesis, inflammation and apoptosis (“ERG - v-ets 
avian erythroblastosis virus E26 oncogene homolog,” 2014; Oikawa & Yamada, 2003). 
Since its discovery it has been shown that TMPRSS2:ERG gene fusions are characteristic 
of PCa that have poorer outcomes and lower survival rates (St. John et al., 2012). This 
finding suggests that TMPRSS2:ERG detection could be a potential prognostic marker 
during PCa screening. It is thought that the TMPRSS2:ERG gene fusion allows for the 
cells to bypass regulation resulting in the over expression of ERG (St. John et al., 2012). 
This will allow the cell to undergo incorrect differentiation forming unregulated and 
unorganized tissue leading to PCa. In a recent study conducted by Hessels et al. it was 
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found that TMPRSS2:ERG fusion transcripts could be detected after DRE (Hessels et al., 
2007). Similar to the PCA3 test, this characteristic of the TMPRSS2:ERG fusion 
transcripts makes it a candidate for PCa screening. Moreover, because of the possible 
application of TMPRSS2:ERG in distinguishing more aggressive and dangerous cancers 
from those that are unlikely to affect a patient, it can be used as a means to reduce the 
overdiagnosis and overtreatment that limit the traditional PSA serum test. 
 
By itself, the screening capabilities of TMPRSS2:ERG transcripts were not much 
better than that of a standard PSA test. When analyzed with the ROC curve, 
TMPRSS2:ERG gene had an AUC of 0.66 compared to that of the traditional PSA 
screening test (0.50-0.66) (Stephan et al., 2013). Although independently it does not 
confer a large increase in accuracy over PSA screening, recently there has been an 
Figure 11 – Biology of TMPRSS2:ERG Fusion: 
The fusion of TMPRSS2 with ERG results in ERG overexpression. Because ERG is implicated in a variety of 
cellular processes involving growth, the overexpression of ERG could open the gates and predispose 
prostate cells harboring this fusion to undergo unregulated growth leading to PCa. 
Figure taken from: St. John, J., Powell, K., Conley-LaComb, M. K., & Chinni, S. R. (2012). TMPRSS2-ERG 
Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate 
Cancer Progression. Journal of Cancer Science & Therapy, 4(4), 94–101. doi:10.4172/1948-5956.1000119 
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increased amount of interest in the use of TMPRSS2:ERG in conjunction with the 
Progensa® PCA3 test as a means to increase the sensitivity of the two tests as both 
biomarkers can be obtained in urine after DRE. Together, PCA3 with TMPRSS2:ERG 
have an AUC value of 0.77 whereas PCA3 by itself has an AUC value of 0.70 (Tomlins 
et al., 2011). Currently, a combination test called Mi-Prostate Score combining PCA3 
score with TMPRSS2:ERG fusion transcript levels and serum PSA levels are being 
offered by the UMICH Health System as a means to screen for PCa (“U-M offers new 
early detection test for prostate cancer,” 2013). This screening method was only recently 
introduced and has yet to be approved by the FDA is under further testing. 
C. Urine Protein Biomarker: Engrailed-2 
The genes for homeodomain-containing transcription factors, also known as HOX 
genes, are a set of genes that function in early embryonic development where they 
determine the identity of cells and tissues and regulate the proliferation of cells (Javed & 
Langley, 2014). It was shown in mouse models that they play an important role in the 
normal development of the prostate gland (Javed & Langley, 2014). A member of a the 
HOX genes, En-2 codes for the Engrailed-2 protein (EN2) that has a multitude of 
functions that range from developmental regulation to survival of dopaminergic neurons 
within the nervous system (Javed & Langley, 2014). Recently implicated in breast 
cancer, it was shown that EN2 is expressed and secreted by PCa cells but not in normal 
prostate tissue (Morgan et al., 2011). As a result, it has become a possible target for use 
in PCa screening. 
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In order for a marker to be useful a screening test situation, it needs to be present 
in easily obtainable samples to be measured. Blood serum or urine are often considered 
the ideal samples in the case of PCa screening. In 2011, Morgan et al. showed that it was 
indeed possible to detect EN2 in urine (Morgan et al., 2011). The researchers collected 
urine samples from 194 patients pre-biopsy and not immediately after DRE (Morgan et 
al., 2011). Using a western blot with anti-EN2 antibodies, they were able to show the 
presence of EN2 in urine. To substantiate this finding, they conducted an ELISA assay 
and obtained the concentrations found in the urine samples collected. Using ROC curve 
analysis, the AUC values were calculated and found to be 0.81 using an EN2 cutoff of 
42.5 ng/ml (Morgan et al., 2011; Pandha et al., 2012). The high AUC value lends to 
EN2’s value as a potential biomarker that is usable for screening for PCa. 
Tumor volume is considered an important factor when PCa are assessed for their 
clinical significance. In a recent study, Pandha et al (2012) showed that EN2 levels 
significantly correlated with PCa tumor size (p = 0.006). Also, it was found EN2 levels 
were significantly higher in higher stage tumors (Pandha et al., 2012). These findings 
point to the possible use of EN2 levels in urine as a means to differentiate between 
benign PCa cases from those that are malignant and aggressive, a crucial differentiation 
that traditional PSA tests failed to do. As such, due to the ease of measuring its levels in 
urine, its PCa specific nature, its high predictive potential for the presence of PCa, and its 
ability to help differentiate between different PCa cancer stages, EN2 is a very promising 
urine biomarker that can be used for PCa screening.  
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DISCUSSION/CONCLUSION 
 
PCa is one of the most prevalent cancers in men worldwide and its early detection 
is essential for treatment success and increased quality of life for patients. The 
introduction of the PSA screening test is a good first step in this direction. However, PSA 
is limited by a variety of factors that include low sensitivity and specificity and its 
inability to differentiate between indolent and aggressive PCa that result in potential 
overdiagnosis and overtreatment of otherwise clinically insignificant cancers. Large 
clinical trials like the PLCO and ERSPC have put the efficacy of the PSA test into 
question and has highlighted the possibility that as much as 50% of the diagnosed PCa 
cases are results of overdiagnosis, many of which undergo treatment (Schröder et al., 
2009). The overdiagnosis and overtreatment leads to not only financial burdens for 
patients and the country’s healthcare system, but also negative physical and 
psychological affects that can adversely affect a patient and his family’s lives. In addition 
to overdiagnosis and overtreatment, the PSA test can also miss clinically significant PCa 
that have PSA levels below the currently accepted 4.0 ng/ml upper normal boundary. 
Currently, PSA is still the preferred PCa screening method. However, many national 
organizations like the USPSTF and the AUA either recommend against its use or 
recommend exercising caution due to possible overdiagnosis and overtreatment issues 
associated with the test. As a result, there is an increased need for alternative methods for 
screening for PCa that will lower the probability of overdiagnosis and overtreatment 
while maintaining a high rate of PCa detection. 
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 There are two approaches to increasing the accuracy of future PCa screening tests. 
One of these is to improve PSA screening itself by exploring the possibility of using 
PSA-derived screening methods. These include altering the age at which to begin 
offering PCa screening to men using the PSA test, using %fPSA, proPSA markers like [-
2]proPSA, or combining PSA with %fPSA and [-2]proPSA in a composite screening test 
called PHI. The tests’ respective performance were acquired via AUC values of ROC 
curves. Of these different methods, creating a EWP zone and using the PHI composite 
test to screen for PCa are the most promising as they had the highest AUC values. Of 
particular note, PHI has the potential to distinguish between aggressive and benign PCa 
with its use of [-2]proPSA which has been shown to be expressed at different levels in 
PCa cases with different GS. %fPSA modified by genetic screening also shows promise, 
but Zambon et al.’s study using KLK3 genetic profiles was the first of its kind and further 
investigation into genetic profiling’s application in PSA screening is needed (Zambon et 
al., 2012).  
Despite these promising results, it is important to understand that these 
modifications to the traditional PSA screening test have their respective disadvantages. In 
the case of establishing EWP zones to further stratify patients based on risk, there is a 
chance that the lowering of the PSA cutoff point from 4.0 ng/ml to 1.5 ng/ml will result 
in an increase in overdiagnosis and overtreatment. As such, a large scale trial will have to 
be conducted in order to assess both the EWP zone’s efficacy in risk stratification and its 
effects on the rates of overdiagnosis and overtreatment. 
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In the case of PHI, the optimal cutoff points for the test are still being debated. 
Also, even though the test is shown to be more accurate than traditional PSA screening 
tests, the cost of the test is more expensive than that of the traditional serum PSA 
screening. It is argued that despite this fact, the added accuracy of the test will offset the 
cost of the test by minimizing costs associated with overdiagnosis and overtreatment. 
However, the fact that PHI is still a relatively new test means that whether or not it can 
decrease the overdiagnosis and overtreatment rates is still unknown. As such, 
investigations into the test’s cost versus benefit are needed. 
 The other way of improving PCa screening is to utilize biomarkers other than 
PSA and those derived from it. One of the various types of biomarkers are epigenetic 
modifications in PCa cells in the form of DNA methylation changes in the promoter 
regions of different genes. The genes that have been shown to be PCa-specific and 
undergo promoter hypermethylation as a consequence of PCa are GSTP1, APC, and 
PTGS2. These epigenetic markers are both highly specific and highly sensitive for PCa. 
Their AUC values are higher than any of the other tests that have been introduced so far. 
The use of the epigenetic markers is limited despite this fact. The high AUC, sensitivity, 
and specificity values were measured using tissue samples acquired from patients. This is 
not ideal for screening tests as it is invasive and difficult to do compared to simple blood 
and urine test. It has been shown that GSTP1 and APC methylation status can be 
measured in urine, albeit resulting in a less accurate prediction of PCa. This limits their 
usefulness in a screening scenario. On the other hand, PTGS2 has not been found to be 
detectable in urine yet, which precludes it from screening tests for PCa. Currently, some 
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researchers suggest the use of gene panels that evaluate the epigenetic profiles of a 
number of genes to increase the specificity of epigenetic screening efforts (Jerónimo et 
al., 2011; Phé et al., 2010). More research is needed to determine the feasibility of using 
urine measurements of epigenetic changes to accurately predict the presence of PCa. 
Also, the discovery of GSTP1, APC, and PTGS2 methylation changes opens the door to 
the discovery of other possible epigenetic biomarkers for use in PCa screening in the 
future.  
The other urine biomarkers for PCa are the PCA3 non-coding mRNA, 
TMPRSS2:ERG gene fusion transcript, and EN2 protein. PCA3 was found to have a 
higher AUC than the currently available PSA-derived screening methods. However, in 
two independent studies, it was found that the AUC values among the %[-2]proPSA, 
PHI, and PCA3 tests were not significantly different. With the discovery of 
TMPRSS2:ERG fusion transcripts in the urine, which by itself confers no real advantage 
in PCa screening over PSA-derived screening tests, researchers have begun to investigate 
the possibility of enhancing PCA3 tests with TMPRSS2:ERG transcript detection. When 
used in conjunction with TMPRSS2:ERG, PCA3 test’s AUC increased with the added 
benefit of potentially differentiating between indolent disease and malignant cancers. 
Whether or not this increase in AUC is significant has yet to be investigated. 
EN2 protein is the final urine biomarker investigated in this study. It is one of the 
most recently described urine biomarkers that has potential to be used in PCa screening. 
The predictive value of EN2 is the highest amongst the currently available tests for early 
PCa detection with an AUC of 0.81 (Morgan et al., 2011; Pandha et al., 2012). EN2 
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levels have also been shown to increase with increasing tumor sizes lending it as a 
possible method to differentiate between indolent disease and one that requires treatment. 
As the result of this investigation into various proposed PSA screening 
improvements and alternatives, it has become clear that no perfect method to screen for 
PCa is currently available. Of all the tests that are presently offered, PHI seem to be the 
most promising. Compared to the other PSA-derived screening tests, PHI has the added 
advantage of being able to distinguish between more clinically advanced cancers from 
less advanced PCa, making it more suitable in a screening scenario to reduce 
overdiagnosis. Even though EN2 based screening seems to have a higher AUC compared 
to that of PHI and thus suggesting it is a better screening method, it is a relatively new 
test that only began testing in the UK and is not yet introduced in the US. Both EN2 and 
PHI have been shown to possess the potential to be also prognostic markers that can 
differentiate between different stages and grades of PCa.  
There are some promising biomarkers such as epigenetic changes in GSTP1 and 
APC genes that have much higher AUC values compared to that of other test and have 
been shown to be in urine samples. However, there have not been many studies yet that 
measure the biomarker’s accuracy in predicting PCa in those samples. As such, 
epigenetics is not a viable strategy for screening PCa currently. However, with more 
research into detecting epigenetic changes in urine and combining multiple genes into a 
single gene panel, epigenetic markers can prove to be the best way to screen for cancer in 
the future due to their high sensitivities and specificities for PCa despite present 
limitations.  
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Saban Research Institute                                Children’s Hospital Los Angeles   
Volunteer Research Associate                                                   Los Angeles, CA 
 
 Discovered novel DNA methylation changes occurring in the urothelium as 
a result of CYP-induced chronic bladder cystitis in CD-1 mice. 
 Investigated possible application of Low Level Laser Therapy (LLLT) for 
treatment of CYP-induced hemorrhagic bladder cystitis in CD-1 mice. 
 Investigated the role of FGF-10 in bladder urothelium wound healing in 
FGFr2b attenuated mice with CYP-induced hemorrhagic cystitis. 
 
Weill Institute of Cell and Molecular Biology                     Cornell University   
Undergraduate Research Assistant                                                    Ithaca, NY 
 
 Adapted and determined optimal conditions for activating and controlling 
fluorescence of Photoactivatable mCherry for protein localization assays in 
Saccharomyces cerevisiae under a confocal light microscope. 
 Investigated the effect of anchoring PtdInsP’s to the plasma membrane on S. 
cerevisiae on phosphatidylinositol phosphate metabolism. 
 
PUBLICATIONS  Choi, I., Yu, K., Jayoung, K., de Guzman, E., Weisenberger, D. J., 
Oghamian, S., Kim, H.J., Lee, K., Laird, P.W., Jones, P.A., Warburton, D., 
Liang, G., & Koh, C.J. Alterations in the DNA Methylation Patterns of 
Calca, Timp3, Mmp2, Line-1 repeats, and Igf2r Associated with Chronic 
Cystitis. (Accepted April 2013 – Urology). 
 Yamazon, J., Lee K., Kuremoto, K., Choi, I., de Guzman, E., Matsunaga, D., 
Yu, K., Bellusci, S., Warburton, D., & Koh, C.J.  Quiescent and CYP-
injured FGFr2b Attenuated Mice Urothelium Suggests Delayed Wound 
Healing with Decreased Fibroblast Growth Factor 10 Signaling. (In 
preparation). 
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ABSTRACTS  
 Choi, I., Yu, K., Jayoung, K., de Guzman, E., Weisenberger, D. J., 
Oghamian, S., Kim, H.J., Lee, K., Laird, P.W., Jones, P.A., Warburton, D., 
Liang, G., & Koh, C.J. (2012 May). Alterations in the DNA Methylation 
Patterns of Calca, Timp3, Mmp2, Line-1 repeats, and Igf2r Associated with 
Chronic Cystitis. American Urological Association Annual Meeting, 
Atlanta, GA. 2012. 
POSTER 
PRESENTATIONS 
 
 Choi, I., Yu, K., Jayoung, K., de Guzman, E., Weisenberger, D. J., 
Oghamian, S., Kim, H.J., Lee, K., Laird, P.W., Jones, P.A., Warburton, D., 
Liang, G., & Koh, C.J. (2012 May). Alterations in the DNA Methylation 
Patterns of Calca, Timp3, Mmp2, Line-1 repeats, and Igf2r Associated with 
Chronic Cystitis. American Urological Association Annual Meeting, 
Atlanta, GA. 2012. 
 Lee, K., Kim, S., Choi, I., Wei, L., de Guzman, E., Yu, K., Fetterman, H., 
Koh, C.J. (October 2011). Low Level Laser Therapy (LLLT) Stimulates 
Enhanced Wound Healing in an Acute Bladder Injury Model. American 
Academy of Pediatrics 2011 National Conference, Boston, MA. 
Yamazon, J., Lee K., Kuremoto, K., Choi, I., de Guzman, E., Matsunaga, 
D., Yu, K., Bellusci, S., Warburton, D., & Koh, C.J. (October 2011). 
FGF10/FGFr2b Signaling in Quiescent Murine Urothelial Maintenance. 
American Academy of Pediatrics National Conference, Boston, MA. 2011. 
SHADOWING 
EXPERIENCE 
July 2011 – July 2012 
 
 
 
Dr. Chester J. Koh, MD (70Hrs.)                  Children’s Hospital Los Angeles 
Los Angeles, CA 
 
 Observed Dr. Koh 8-10 hours every few weeks in the Operating Room (OR) 
 Operated mobile X-Ray machine during operations 
 Prepared operation rooms for surgery 
VOLUNTERRING 
EXPERIENCE 
March 2013 – August 
2013 
 
 
 
 
 
 
 
 
March 2013 – August 
2013 
 
 
 
 
 
 
August 2008 
 
 
Massachusetts General Hospital Volunteer Office              Boston, MA 
 
 Help in the coordination of volunteers in various volunteering assignments 
 Maintain profiles of volunteers in an effort to help the office stay up to date 
with document and health regulations compliance of individual volunteers 
 Answer any general phone calls directed to the volunteer office 
 Answer any inquiries about various volunteer programs at MGH 
 Help respond to urgent requests for volunteers by various departments 
within MGH 
 
MGH Bone Marrow Transplant Clinic Volunteer  Boston, MA 
 
 Maintain food and refreshment stocks at the BMT clinic for patient use 
 Offer food and drinks to patients within the clinic 
 Engage in friendly conversation with any patients who desire to talk in an 
effort to make patients and significant others feel welcome and comfortable 
 Support staff on an as-needed basis 
 
PREPARE International Orientation Group Leader         Cornell University             
 73 
 
Ithaca, NY 
 Advised a group of 15-20 international students in the College of Arts and 
Sciences about academic options and living a foreign country 
LEADERSHIP AND 
ORGANIZATIONS 
January 2013 – August 
2013 
 
 
 
 
 
 
June 2009 – May 2011 
 
 
 
 
 
 
 
 
 
 
 
April 2008 – April 
2009 
 
 
 
 
 
 
 
 
SASE Professional Chapter Boston                                                 Boston, MA 
 
 Co-founder of SASE Professional Chapter Boston 
 Organized interest meetings 
 Organized initial leadership team 
 Oversee the planning of various social/networking, community 
service/mentoring, and professional development events by focus groups 
 
SASE Cornell Chapter Co-President & Treasurer             Cornell University                        
Ithaca, NY 
 Founded SASE Cornell with three other undergraduates 
 Allotted and maintained organization’s budget and reimbursements 
 Organized fall and spring volunteering events, fundraisers and workshops 
 Planned first Annual SASE Northeast Regional Conference at 
Massachusetts Institute of Technology 
 Advised members from the College of Arts and Sciences regarding 
academics, development of interpersonal skills and advancement in 
academic skills 
 Helped create and maintain SASE Cornell’s website and Facebook page 
 
Cornell Taiwanese-American Society Culture Chair         Cornell University 
                                                                                                               Ithaca, NY 
 Orchestrated and planned CTAS Taiwanese culture show 
 Created and organized culture show’s budget and reimbursements 
 Penned and directed music videos for culture show 
 Assisted in devising CTAS’s participation in Asia Night 2009, a university-
wide showcase of Asian organizations 
TECHNICAL 
SKILLS 
Laboratory:  
• Maintaining S. cerevisiae and E. coli cultures  
• Gene cloning through  plasmid amplification • Media preparation  
• Gel Electrophoresis • Western Blotting • Comassie Assays • Northern Blotting 
• DNA extraction and purification • PCR • RT-PCR  
• DNA sequencing • Enzyme assays • Protein localization assays • Dialysis  
• Chromatography • Pyrosequencing • Mouse genotyping • Mouse breeding  
• Murine Bladder • Extraction • PCNA expression detection  
• Preparation of Histological Sections • H&E staining Luminex cytokine assay  
• TUNEL assay • Quantitative Methylation-Sensitive Real Time PCR 
(MethyLight)  
 Laboratory Instruments: Light microscopes • Centrifuges • RT-PCR 
equipment • Luminex 
 
 Computer: Microsoft Office Suites • Knowledge of Microsoft Windows and 
Mac OS X 
 
LANGUAGES  Bilingual in English and Mandarin 
